Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 7411-7420 Newer>

Chemistry World May 4, 2011 Andrew Turley	Teva sidelines Valeant with $6.8bn Cephalon bid US drugmaker Cephalon has agreed to a $6.8 billion ( 4.1 billion) takeover bid from Israeli generics manufacturer Teva, which has beaten into second place Canadian pharma company Valeant.
Chemistry World May 4, 2011 Hepeng Jia	Animal testing alternatives for China 'China can lead the way in applying alternatives to animal testing,' says Melvin Andersen, a professor of toxicology from the Hamner Institute for Health Sciences, North Carolina, in the US, speaking at a Unilever sponsored meeting in Shanghai, on 14 March.
The Motley Fool May 4, 2011 Brian Orelli	VIVUS Unveils Its Obesity Plans Investors are getting fat on the news that VIVUS has a plan, and a backup plan, to get its obesity drug Qnexa on the market.
The Motley Fool May 3, 2011 Brian Orelli	Brakes Are Off at Dendreon Ramping up sales, one month at a time.
The Motley Fool May 3, 2011 Brian Orelli	Teva's Branded-Drug Binge For a company that's a generic-drug maker, Teva Pharmaceuticals sure does like its branded drugs. Despite the warts the company is ponying up $6.2 billion to buy Cephalon.
The Motley Fool May 3, 2011 Arundhati Parmar	Medtronic Is Target of New Senate Finance Committee Investigation The Senate scrutiny comes at a time when both parties are looking at entitlement reform, including how to overhaul Medicare and Medicaid.
The Motley Fool May 2, 2011 Brian Orelli	StemCells Up for All the Right Reasons Federal funding doesn't matter for most stem cell companies.
The Motley Fool May 2, 2011 Anupama Pattanaik	J&J Attempts to Create Major "Synthes"-is Johnson & Johnson will acquire the medical device maker for $21.3 billion.
The Motley Fool May 2, 2011 Cindy Johnson	Pacific Biosciences of California Shares Plunged: What You Need to Know Pacific Biosciences of California dropped 12% in intraday trading today after a news article on hot stock Illumina suggested industry competition is intensifying.
The Motley Fool May 2, 2011 Tim Beyers	Spectrum Pharmaceuticals Shares Popped: What You Need to Know Shares of Spectrum Pharmaceuticals rose as much as 14% in intraday trading after the Food and Drug Administration approved Fusilev as a colon cancer treatment.
<Older 7411-7420 Newer> Return to current articles.